The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a huge mover today! About 3.87 million shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 116.51% since March 9, 2016 and is uptrending. It has outperformed by 109.09% the S&P500.
The move comes after 5 months negative chart setup for the $2.41 billion company. It was reported on Oct, 12 by Barchart.com. We have $12.38 PT which if reached, will make NASDAQ:ARIA worth $120.50 million less.
Analysts await Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to report earnings on November, 1. They expect $-0.20 EPS, up 31.03% or $0.09 from last year’s $-0.29 per share. After $0.57 actual EPS reported by Ariad Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -135.09% negative EPS growth.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage
Out of 5 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 4 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 80% are positive. Ariad Pharmaceuticals has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was maintained by JP Morgan on Friday, August 7 with “Neutral”. The rating was initiated by Leerink Swann on Monday, September 26 with “Outperform”. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Buy” rating by Suntrust Robinson on Wednesday, October 5. On Wednesday, October 5 the stock rating was initiated by SunTrust with “Buy”. The firm has “Underweight” rating given on Friday, July 29 by Barclays Capital. Barclays Capital maintained it with “Underweight” rating and $8 target price in Wednesday, May 11 report. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Underweight” rating by Barclays Capital on Tuesday, January 19. JMP Securities maintained the shares of ARIA in a report on Wednesday, March 9 with “Market Outperform” rating.
According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.73, from 0.67 in 2016Q1. The ratio increased, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
The Florida-based Raymond James Fincl Svcs Advisors Incorporated has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Quantitative Mgmt Ltd Company holds 85,200 shares or 0.03% of its portfolio. Fiera Capital, a Quebec – Canada-based fund reported 16,005 shares. Cornerstone Capital Management Holding Ltd holds 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 35,517 shares. Moreover, Tekla Capital Mngmt Ltd Liability Corp has 0.15% invested in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 502,000 shares. Kcg Hldgs last reported 150,016 shares in the company. Teacher Retirement Sys Of Texas last reported 0% of its portfolio in the stock. Price T Rowe Assocs Md accumulated 0% or 74,300 shares. Da Davidson And Company owns 400 shares or 0% of their US portfolio. Los Angeles Capital Management And Equity Rech has 14,545 shares for 0% of their US portfolio. Guggenheim Capital Limited Company accumulated 352,467 shares or 0.01% of the stock. Vanguard Grp Incorporated Incorporated accumulated 12.72M shares or 0.01% of the stock. Millennium Management Limited accumulated 256,117 shares or 0% of the stock. Commonwealth Equity Services accumulated 23,429 shares or 0% of the stock. Rhumbline Advisers holds 0% or 188,563 shares in its portfolio.
Insider Transactions: Since April 22, 2016, the stock had 1 insider purchase, and 12 sales for $3.87 million net activity. CLACKSON TIMOTHY P had sold 11,700 shares worth $83,478. 26,990 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares with value of $199,996 were bought by Panayiotopoulos Paris. 108,569 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares with value of $896,135 were sold by Radaelli Massimo. On Monday, June 13 LAVIDAS ATHANESE sold $626,039 worth of the stock or 76,250 shares.
More news for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) were recently published by: Prnewswire.com, which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 07, 2016. Forbes.com‘s article titled: “ARIAD Pharmaceuticals Reaches Analyst Target Price” and published on September 15, 2016 is yet another important article.
ARIA Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.